Stockwinners Market Radar for April 13, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:58 EDT Teva discloses FDA Complete Response Letter to partner Alvotech for AVT02 - The company states: "Teva Pharmaceutical (TEVA) announced that the FDA has issued a complete response letter to its partner Alvotech (ALVO) for the Biologics License Application for AVT02, a high-concentration biosimilar candidate for Humira(R) (adalimumab). The CRL stated that the application could not be approved at this time based on deficiencies associated with Alvotech's manufacturing facility that must be satisfactorily resolved. Additional review of the details following the recent FDA's re-inspection and CRL are being assessed to determine next steps. While this outcome is disappointing, Teva remains fully committed to its leadership in biosimilars and the partnership with Alvotech. The Company remains optimistic about additional compounds in the pipeline and further progress with AVT02."

19:50 EDT InterPrivate IV Infratech Partners Inc trading halted, news pending

18:23 EDT Lamb Weston CEO: I feel great about where the business is right now - In an interview on CNBC's Mad Money, Tom Werner said Lamb Weston is making big investments around the globe to expand capacity. It just returned its margin structure to pre-pandemic levels. The company's retail business has grown substantially over the past five years, he noted.

18:06 EDT FedEx director buys $249K in common stock - In a regulatory filing, FedEx disclosed that its director Stephen Gorman bought 1.08K shares of common stock on April 12th in a total transaction size of $249K.

17:46 EDT Barnes & Noble Education CFO Thomas Donohue submits resignation - On April 12 ,Thomas D. Donohue submitted his resignation as Executive Vice President, Chief Financial Officer of Barnes & Noble Education effective as of April 28, to pursue other opportunities and interests. There were no disagreements between the Company and Mr. Donohue on any matter related to the Company's operations, policies or practices, nor are any separation-related compensation payments contemplated. The Company has launched an external search and, in the interim, Mr. Donohue's former duties will be performed by the Company's existing finance team under the supervision of Michael Huseby, the Company's Chief Executive Officer, with ongoing oversight from the Audit Committee of the Company's Board of Directors. Reference Link

17:37 EDT Lockheed Martin awarded $172.1M Navy contract modification - Lockheed Martin was awarded a $172.1M modification to a cost-plus-fixed-fee, firm-fixed-price order against a previously issued basic ordering agreement. This modification definitizes the order and adds scope to provide special test/tooling equipment for increasing Block 4 manufacturing capacity, as well as procures material modification kits in support of removing life limits, correcting deficiencies, and retrofitting aircraft to incorporate Next Gen Distributed Aperture System hardware and associated Power and Thermal Management System modifications efforts. These modifications are in support of F-35 aircraft for the Air Force, Marine Corps, Navy, Foreign Military Sales customers, and non-U.S. Department of Defense, or DOD, participants. Work was expected to be completed in December 2030 The Naval Air Systems Command, Patuxent River, Maryland, is the contracting activity.

17:25 EDT General Dynamics to compete for orders on $344.22M Army contract - General Dynamics and IMT Defense Corp. will compete for each order of the $344.22M fixed-price with economic price adjustment contract for the manufacture, test, packaging and delivery of 155 mm M1128 artillery metal parts assembly. Bids were solicited via the internet with two received. Work locations and funding will be determined with each order, with an estimated completion date of April 13, 2028. U.S. Army Contracting Command is the contracting activity.

17:12 EDT Consolidated Communications confirms "take private" proposal from Searchlight - The company states: "Consolidated Communications announced that its board of directors received a non-binding proposal letter, dated April 12, 2023, from Searchlight Capital Partners, L.P. and British Columbia Investment Management Corporation to acquire all of the outstanding common shares of Consolidated not already owned by the Searchlight Group for cash consideration of $4.00 per share. Searchlight owns 34.3% of the Company's outstanding common shares, based on their most recent Schedule 13D filing dated April 12, 2023. The Board intends to establish a special committee consisting of independent directors of the Board to review and consider the proposal, as well as any other alternative proposals or other strategic alternatives that may be available to the Company."

17:08 EDT Agree Realty announces 1.3% increase in monthly dividend to 24.3c per share - Agree Realty announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of 24.3c per common share, representing a 1.3% increase over the previous monthly dividend. The monthly dividend reflects an annualized dividend amount of $2.916 per common share, representing a 3.8% increase over the annualized dividend amount of $2.808 per common share from the second quarter of 2022. The dividend is payable May 12 to stockholders of record at the close of business on April 28.

17:02 EDT Anika announces cooperation agreement with Caligan, $20M share repurchase plan - Anika Therapeutics announced that it has entered into a cooperation agreement with Caligan Partners. As part of the agreement, the company appointed Gary Fischetti as a Class III director. Fischetti will join two existing board members on a newly formed capital allocation committee of the board, which will make recommendations to the board and support management's review of the company's capital allocation. With this appointment, the Anika board is expanding to eight directors, including six new independent directors appointed since 2018. In addition, the board has authorized a $20M share repurchase program, $5M of which will be effected through an accelerated repurchase program and $5M of which will be purchased in the open market over the next 12 months, subject to prevailing stock prices, general economic and market conditions, and other considerations. The remaining $10M of the authorization will be purchased in the open market over the next 12 months subject to the company generating positive cash flow. This buyback replaces the company's share repurchase program that was announced in May 2019.

17:01 EDT Five Below director sells $4.38M in common stock - In a regulatory filing, Five Below disclosed that its director Thomas Vellios sold 20K shares of common stock on April 11th in a total transaction size of $4.38M

16:58 EDT Cutera to hold 'special meeting' to consider proposals on 'Targeted Directors' - Cutera announced it will hold a Special Meeting of Stockholders on June 9, at 9:00 am PT in or near Brisbane, California for the purpose of considering proposals offered by J. Daniel Plants and David Mowry to remove, without cause, five of the six directors who were independent at the time of receiving the notices . As previously announced, the Board has empaneled a Special Committee of the Board of Directors to consider the Special Meeting notices provided by Mr. Plants and Mr. Mowry and to provide stockholders with a recommendation on how to vote on the proposals at any such Special Meeting. Chair of the Special Committee Juliane T. Park commented, "The Special Committee welcomes the input of Cutera stockholders and is confident that, once fully informed, they will strongly support the Targeted Directors who have been diligently serving the interests of all Cutera stockholders." The Special Committee will provide its recommendation in respect of the Special Meeting to stockholders in due course. Additional details will be made available in the Company's definitive proxy statement to be filed with the SEC in connection with the Special Meeting. Stockholders are not required to take any action at this time.

16:51 EDT DOJ says Adobe agrees to pay $3M to settle kickback allegations - Adobe has agreed to pay $3M to resolve False Claims Act allegations that it made payments in violation of the Anti-Kickback Act in return for influence over the sale of Adobe software to the federal government. "Those who do business with the government are prohibited from paying kickbacks, which can result in unnecessary purchases and increase costs to taxpayers," said Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department's Civil Division. "We will continue to use all appropriate tools to safeguard the integrity of the federal procurement process." The settlement announced today resolves allegations that Adobe made improper payments under its Solution Partner program to companies that had a contractual or other relationship with the government that allowed them to influence federal purchases of Adobe software. Between January 2011 and December 2020, Adobe allegedly paid the companies a percentage of the purchase price of the software. The United States contends that these payments constituted prohibited kickbacks that resulted in Adobe causing false claims for payment to be submitted to federal agencies. The resolution obtained in this matter was the result of a coordinated effort between the Justice Department's Civil Division, Commercial Litigation Branch, Fraud Section, and the U.S. Attorney's Office for the District of Columbia, with assistance from the GSA-OIG and the Defense Criminal Investigative Service. Reference Link

16:34 EDT Blue Safari Group Acquisition, Bitdeer complete business combination - Bitdeer Technologies and Blue Safari Group Acquisition (BSGA) announced the completion of their previously announced business combination. Bitdeer's Class A ordinary shares will commence trading on the Nasdaq under the ticker symbol (BTDR) on April 14.

16:31 EDT Eli Lilly issues complete response letter for mirikizumab BLA in colitis - Eli Lilly announced the FDA has issued a complete response letter for the mirikizumab biologic license application - BLA - for the treatment of ulcerative colitis. In the letter, the FDA cited issues related to the proposed manufacturing of mirikizumab, with no concerns about the clinical data package, safety, or label for the medicine. Lilly recently received approval for mirikizumab as a first-in-class treatment for adults with moderately to severely active UC in Japan. In addition, the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for mirikizumab as a first-in-class treatment for adults with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment. Regulatory decisions are anticipated in additional markets around the world in 2023.

16:21 EDT Nurix Therapeutics advances almost 4% after reporting Q1 results and update - Shares of Nurix Therapeutics are up 3.65% or 37c to 10.50 per shares in after hours trading on Thursday after reporting quarterly results ahead of analyst estimates.

16:18 EDT DavidsTea to delist from Nasdaq - DavidsTea confirmed that it is voluntarily delisting from Nasdaq and that its common shares will stop trading on Nasdaq at the close of market on Friday, April 14. As previously announced, DavidsTea commenced trading on the TSX Venture Exchange on Monday, April 3 under the ticker symbol (DTEA). After April 14, DavidsTea will be listed only on the TSXV, where its shares trade in Canadian dollars. Shareholders in the United States and other U.S. investors are able to trade DAVIDsTEA through the facilities of the TSXV.

16:16 EDT Express, WHP Global to acquire Bonobos from Walmart in $75M deal - Express (EXPR) and global brand management firm WHP Global announced a definitive agreement to acquire menswear brand Bonobos, Inc. from Walmart (WMT). This is the first acquisition to be made jointly by WHP Global and EXPR since finalizing their strategic partnership earlier this year. "Our strategic roadmap to transform EXPR to create shareholder value includes achieving profitable growth in our core Express business - which is our first priority - optimizing our omnichannel platform, and accelerating our growth and profitability through our partnership with WHP Global," said Tim Baxter, EXPR Chief Executive Officer. WHP Global and EXPR have entered into a definitive agreement with Walmart Inc. to acquire Bonobos, Inc. for a combined purchase price of $75M. WHP Global will acquire the Bonobos brand for a purchase price of $50M. EXPR will acquire the operating assets and assume the related liabilities of the Bonobos business for a purchase price of $25M. Concurrent with the closing of the transaction, WHP Global and EXPR will enter into an exclusive long-term license agreement with multiple renewal options granting EXPR the right to use the intellectual property acquired by WHP Global for the operation of the Bonobos business in the U.S. in exchange for EXPR's payment of a royalty fee to WHP Global. The transaction is expected to close in EXPR's second fiscal quarter of 2023, subject to customary closing conditions.

16:16 EDT ClearPoint Neuro announces ANVISA approval of Neuro Navigation portfolio - ClearPoint Neuro announced successful registration of its Neuro Navigation portfolio with the Brazilian regulatory body, Agencia Nacional de Vigilancia Sanitaria, or ANVISA.

16:10 EDT Motus GI implements reductions in executive management, clinical expenses - To help ensure adequate financial resources are available to the company, Motus GI has implemented additional cost-cutting measures to preserve capital. The primary cuts are attributable to reductions in executive management and clinical expenses. These changes are expected to reduce quarterly operating costs by approximately 25% on a go-forward basis. The company expects to incur certain non-recurring charges related to these cost-cutting measures of less than $400,000 in the second quarter. The cost reduction measures announced today are in addition to the strategic restructuring program announced in January. "We continue to make necessary decisions to support the Company's R&D, regulatory and commercial strategies during what has been a difficult financial market for many companies to raise capital. It is our unyielding belief in the technology and products we've developed that allows us to remain focused on the long-term opportunity we see in the market. In the near-term, we will continue to develop our Pure-Vu EVS platform with the focus on the Upper GI indication and continue our discussions with potential partners that will expand our commercial reach, and adoption of the Pure-Vu EVS System across the United States," commented Moran. "To enable our continued progress, it's imperative that we judiciously reduce our operating expenses and extend our cash runway to execute platform advancements. I am confident that Mark's significant operational experience, industry knowledge and exceptional leadership skills make him the ideal candidate to lead Motus GI through this next phase. I look forward to working closely with Mark and the rest of our talented team to continue delivering innovative endoscopic solutions that transform patient care."

16:07 EDT Lucid Group produced 2,314 vehicles, delivered 1,406 vehicles during Q1 - Lucid Group announced production and delivery totals for the quarter ended March 31. The company produced 2,314 vehicles during Q1 at its manufacturing facility in Arizona and delivered 1,406 vehicles during the same period.

16:06 EDT Purple Innovation announces cooperative framework with Coliseum Capital - Purple Innovation announced that it has entered into a binding Memorandum of Understanding to establish a cooperative governance framework with Coliseum Capital Management, LLC, the largest stockholder of the company owning approximately 44% of its common stock. Under the terms of the Planned Cooperation Agreement, which is anticipated to be executed promptly, the Purple Board of Directors will be reconstituted to consist of eight directors. Five of the directors currently serve on the Board: Adam Gray, CEO Robert T. DeMartini, Gary T. DiCamillo, Claudia Hollingsworth and Dawn Zier. The three additional directors who will join were previously nominated by Coliseum in connection with the Company's 2023 annual meeting of stockholders: S. Hoby Darling, R. Carter Pate and Erika Serow. Mr. Gray will become Board Chair, while Mr. DiCamillo will continue to serve as Lead Independent Director and will become Chair of the Nomination and Governance Committee. Concurrently, Paul Zepf and Pano Anthos will resign as directors of the Company. Scott Peterson, who is a significant stockholder and has served as Board Observer since Purple's September 2022 acquisition of Intellibed, will be a nominee on the Board's slate of directors at the 2023 Annual Meeting in place of Dawn Zier, who previously announced her intention not to stand for reelection. The Company will recommend that stockholders vote in favor of its eight-person Board slate at its 2023 Annual Meeting. Coliseum has committed to vote in favor of the Company's slate of directors.

15:26 EDT Warner Bros.' 'Suicide Squad' game delayed to February 2024 - Warner Bros. Discovery's (WBD) Rocksteady Studios announced that upcoming DC comics game "Suicide Squad: Kill the Justice League" has been delayed to February 2, 2024 after initially being slated for a May 2023 release. "We have made the tough but necessary decision to take the time needed to work on getting the game to be the best quality experience for players," the game developer said. The title is set to release for PC, Xbox Series X/S (MSFT), and PlayStation 5 (SONY). Reference Link

14:44 EDT Twitter to allow users to offer subscriptions of content in monetization effort - Elon Musk, who owns Twitter, said on Thursday, that users of the social media app may "Apply to offer your followers subscriptions of any material, from longform text to hours long video! that followers subscriptions to content, including long-form text and hours-long video." Musk continued in the tweet; "For the next 12 months, Twitter will keep none of the money. You will receive whatever money we receive, so that's 70% for subscriptions on iOS & Android (they charge 30%) and ~92% on web (could be better, depending on payment processor). After first year, iOS & Android fees drop to 15% and we will add a small amount on top of that, depending on volume. We will also help promote your work. Our goal is to maximize creator prosperity." Reference Link

14:16 EDT Cushman & Wakefield appoints Noelle Perkins as General Counsel - Cushman & Wakefield has appointed Noelle Perkins as Executive Vice President, General Counsel & Corporate Secretary, effective July 1. In this role, Perkins will provide strategic advice, guidance, oversight and support to the firm's global business and operations. She will lead Cushman & Wakefield's global legal function, playing a critical role in implementing governance and risk management practices for the firm.

14:02 EDT L3Harris reports contract to build geostationary weather satellite sensors - L3Harris Technologies announced that it received a contract to provide next-generation geostationary imaging and sounding instruments for the Japan Meteorological Agency. "The award continues L3Harris' legacy of producing critical space-based weather instruments for Japan. Under the terms of the contract with the Mitsubishi Electric Group, L3Harris will build and deliver an advanced imager and sounder for JMA's Himawari-10 satellite. The imager will use a similar technical platform as L3Harris' Advanced Baseline Imager on NOAA's Geostationary Operational Environmental Satellite-R, or GOES-R. The imager will also carry enhancements beyond its predecessor, Himawari-8/-9, including tailored Japanese spectral bands to supply the most advanced geostationary weather information for the international community," the company stated. The Himawari-10 imager and sounder will be developed and built at L3Harris' Fort Wayne, Indiana facilities, the company noted.

13:10 EDT Digital Brands to share news on Sundry acquisition, cash flow on Thursday - Hil Davis, the CEO of Digital Brands, said via Twitter that the company will share news on the Sundry acquisition and cash flow in a press release on Thursday with a conference call on Monday at 4pm ET. Reference Link

12:37 EDT Dechra confirms possible 4,070 GBp per share offer from EQT - Dechra Pharmaceuticals and EQT note the recent press speculation and confirm that they have entered into discussions with respect to a possible all-cash recommended offer for the entire issued, and to be issued, ordinary share capital of Dechra by EQT. Under the terms of the possible offer, Dechra shareholders would receive 4,070 pence per ordinary share in cash. In the event that a firm offer is made, it is currently being discussed that the private equities investment department of the Abu Dhabi Investment Authority would be a co-investor with EQT, the companies said in a statement. The board of Dechra has confirmed to EQT that it is prepared, subject to the finalization of all relevant terms in a manner satisfactory to it, to provide a recommendation at the possible offer price indicated should EQT announce a firm intention to make an offer.

12:04 EDT Luminar announces 'successful build-out and bring-up' of facility in Monterrey - Luminar announced the "successful build-out and bring-up of a new highly automated, high-volume manufacturing facility in Monterrey, Mexico." In a post to its corporate website, the company stated that "the first Luminar Iris sensors out of this new dedicated facility are beginning to ship to Luminar's lead global high-volume series production customer in preparation for start of production by end of this year to support vehicle launches." Reference Link

12:00 EDT Progressive falls -6.5% - Progressive is down -6.5%, or -$9.69 to $138.47.

12:00 EDT Daily S&P Biotech Bear 3x Shares falls -13.6% - Daily S&P Biotech Bear 3x Shares is down -13.6%, or -$2.87 to $18.25.

12:00 EDT Volaris rises 8.9% - Volaris is up 8.9%, or $1.00 to $12.26.

11:43 EDT Ubisoft+ officially available on Xbox consoles - Microsoft (MSFT) said that Ubisoft+, Ubisoft's (UBSFY) game subscription service, is officially available on Xbox consoles through Ubisoft+ Multi Access. In order to take advantage of this new option, Xbox users must be subscribed to Ubisoft+ Multi Access and connect their account to their Xbox profile. "Partnering with Xbox to launch Ubisoft+ Multi Access on Xbox consoles enhances our subscription offering to provide more value and choice to our players," said Ubisoft Senior Vice President of Strategic Partnerships and Business Development, Chris Early. "Xbox console players now have access to our worlds through Ubisoft's extensive game library." Reference Link

11:10 EDT Tingo Group regains compliance with Nasdaq minimum bid price rule - Tingo Group announced that it has received a Bid Price Compliance Letter from The Nasdaq Stock Market informing Tingo that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. As announced on Monday, April 10, 2023, Tingo was previously notified by Nasdaq that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days, as required by the Nasdaq Listing Rules. To regain compliance with the Rule, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. This requirement was met on April 12, 2023, the tenth consecutive trading day of MICT's common stock bid price closing above $1.00.

10:54 EDT Consolidated Communications jumps 38% after Searchlight offers $4 per share - In a regulatory filing earlier, Searchlight Capital Partners, which holds a 34.3% stake in Consolidated Communications, disclosed that on April 12, Searchlight Capital Partners, on behalf of its affiliated investment funds, and British Columbia Investment Management Corporation submitted to the board of directors of the company a letter setting forth a non-binding proposal to acquire all of the outstanding shares of common stock of the company that are not owned by Searchlight or BCI for cash consideration of $4.00 per share of common stock. "While the proposal remains under consideration by the board and a special committee thereof referred to in the proposal, the reporting persons and their affiliates and representatives expect to discuss the proposal and related matters with the company, the board, the special committee and their respective representatives, as well as potential equity financing sources, shareholders and other interested parties. The reporting persons do not intend to provide additional disclosures regarding the proposal until a definitive agreement has been reached unless disclosure is otherwise required under applicable U.S. securities laws," the filing stated. In morning trading following the disclosure, shares of Consolidated Communications have jumped $1.04, or 38%, to $3.80. Reference Link

10:32 EDT Delta doesn't share 'anxiety' about domestic demand for the summer

10:18 EDT Delta sees completing FY planned debt reduction in 1H

10:13 EDT Delta Air Lines working to ensure resiliency, says CEO

10:06 EDT Microvast announces appointment of Isida Tushe as general counsel - Microvast Holdings announced the appointment of Isida Tushe as General Counsel and Corporate Secretary. "We are pleased to have someone of Isida's caliber and expertise join the team at Microvast," said Microvast Chairman, CEO, and founder, Yang Wu. "Isida's extensive experience and proven track record will serve the Company well as we continue to drive innovation and advance our growth."

10:00 EDT LSB Industries falls -7.5% - LSB Industries is down -7.5%, or -76c to $9.26.

10:00 EDT LG Display rises 5.9% - LG Display is up 5.9%, or 36c to $6.50.

10:00 EDT Coeur Mining rises 7.1% - Coeur Mining is up 7.1%, or 30c to $4.50.

09:53 EDT SunPower announces financing commitments of over $450M for loan program - SunPower (SPWR) last night announced that it has secured financing commitments of more than $450M for its residential solar and storage loan program from HASI (HASI) and Credit Agricole CIB. The vehicle will acquire loans made to SunPower customers and is non-recourse to SunPower. the company said in a statement. Through this transaction, SunPower Financial "will continue to provide customers with attractive loan options at tenors up to 25 years for their transition to a cleaner and lower-cost future," it added. "We continue to build and strengthen our suite of world-class financing products to meet growing demand. This new transaction also illustrates the health and resilience of consumer credit markets during the recent period of shifting conditions," said Guthrie Dundas, SunPower interim Chief Financial Officer.

09:47 EDT Infosys falls -7.8% - Infosys is down -7.8%, or -$1.33 to $15.74.

09:47 EDT LG Display rises 4.7% - LG Display is up 4.7%, or 29c to $6.43.

09:47 EDT Gaotu Techedu rises 5.9% - Gaotu Techedu is up 5.9%, or 21c to $3.73.

09:19 EDT Medigus jumps 21% after acquiring 19.9% of Metagramm Software - Shares of a Medigus are up 21% in pre-market trading at $5.10. The company has announced that it has "acquired 19.9% of Metagramm Software Ltd., an innovative AI, machine learning communication and grammar assistant software. In return, Medigus paid Metagramm $250,000 in Medigus' common shares. Metagramm is one of the first companies to develop grammar and language assistance tools and technology for users. Metagramm has an advanced grammar engine based on proprietary AI algorithms and natural language processing technology. Metagramm offers tools for writing and reviewing, grammar, spelling, punctuation and style features as well as translation and multilingual dictionaries."

09:16 EDT Blink Charging awarded $7M to implement new ride share service in New Jersey - Blink Charging announced the New Jersey Department of Environmental Protection, NJDEP, New Jersey Board of Public Utilities, NJBPU, and New Jersey Economic Development Authority, NJEDA, have awarded Blink $7M in Regional Greenhouse Gas Initiative, RGGI, auction proceeds, to bring electric ride-sharing to New Jersey communities that lack access to reliable transportation. The award is part of the overall $70M in Regional Greenhouse Gas Initiative, RGGI, auction proceed awards aimed to help reduce the upfront costs of electric trucks, buses, and equipment in underserved neighborhoods. "Bringing an electric ride share program to New Jersey makes great sense and will be a benefit to the low- to moderate-income communities that may lack access to traditional public transportation. We are excited to have been selected and share our expertise and experience in the electric ride share space," said Michael Farkas, Founder and Chief Executive Officer of Blink Charging. "Electric ride share services make a positive impact for residents in underserved areas by reducing harmful greenhouse gas pollutants that come from gas fueled vehicles."

09:15 EDT AMD announces AMD Radeon PRO W7000 Series graphics - AMD announced the AMD Radeon PRO W7000 Series graphics, its most-powerful workstation graphics cards to date. The AMD Radeon PRO W7900 and AMD Radeon PRO W7800 graphics cards are built on "groundbreaking AMD RDNA 3 architecture, delivering significantly higher performance than the previous generation and exceptional performance-per-dollar compared to the competitive offering," the company said. The new graphics cards are designed for professionals to create and work with high-polygon count models seamlessly, deliver incredible image fidelity and color accuracy, and run graphics and compute-based applications concurrently without disruption to workflows.

09:13 EDT Verizon continues to upgrade Memphis, TN's network - Verizon has recently made major upgrades to the network serving customers in Memphis, TN. These upgrades are part of a multi-year redesign of its network architecture to stay ahead of exponential data usage increases, upgrade the technology in the network, and to pave the way for personalized customer experiences. Network upgrades in Memphis include deploying new cell sites to extend coverage and capacity in local communities. "Today's world calls for faster speeds, ultra secure connections and improved coverage in more places. We're dedicated to bringing the best and latest technologies to local communities, and to keeping our customers connected through 5G," said Eric Lia, Vice President of Engineering and Operations for Verizon.

09:12 EDT Editas Medicine appoints Reeve as Chair of Board, Levy as new director - Editas Medicine (EDIT) announced the appointment of current Independent Director Emma Reeve as Chair of the Board, effective at the Company's next annual stockholder meeting, currently scheduled for June 1. Reeve will be replacing James Mullen as he steps down from the Board and his role as Executive Chair. The Company also announced the appointment of Elliott Levy, M.D., to its Board of Directors as an independent director. Most recently, Reeve served as Chief Financial Officer of Constellation Pharmaceuticals. Dr. Levy served as Senior Vice President and Head of Global Development and R&D Strategy and Operations at Amgen (AMGN) from 2014-2021.

09:10 EDT Amylyx: First person dosed in AMX0035 trial for Wolfram Syndrome treatment - Amylyx Pharmaceuticals announced that the first participant has been dosed in the HELIOS study, a Phase 2 clinical trial of AMX0035 and taurursodiol for the treatment of Wolfram syndrome . HELIOS is an exploratory open-label proof of biology study assessing the effect of AMX0035 safety and tolerability, and various measures of endocrinological, neurological and ophthalmologic function. Amylyx anticipates topline results from HELIOS in 2024. "WS is a rare, progressive, and often fatal neurodegenerative disease. Preclinical data showed that a combination treatment of two chemicals, namely AMX0035, may restore cellular functioning in a cellular model of WS," said Fumihiko Urano, MD, PhD, Principal Investigator of the HELIOS clinical trial, and Professor of Medicine and of Pathology and Immunology in the Division of Endocrinology, Metabolism & Lipid Research at Washington University School of Medicine. "There continues to be a significant unmet need for people living with WS and we look forward to building upon our preclinical findings as part of HELIOS to explore the safety, tolerability, and preliminary clinical activity in people living with WS."

09:08 EDT Chevron, Angelicoussis enter JSA to explore ammonia transportation - Chevron, through its subsidiary Chevron Shipping, and the Angelicoussis Group, through its Energy Transition division, Green Ships, announced a joint study agreement, or JSA, to explore how tankers can be used to transport ammonia, a potential lower carbon marine fuel. The initial study will evaluate the ammonia transportation market, existing infrastructure, the safety aspects of ammonia, potential next generation vessel requirements and a preliminary system to transport ammonia between the U.S. Gulf Coast and Europe. Future opportunities will focus on additional global markets. Ammonia is a carrier of hydrogen and is believed to have potential to lower the carbon intensity of the marine industry. Through the JSA, the Angelicoussis Group and Chevron aim to advance ammonia's technical and commercial feasibility at scale, particularly as an export for petrochemicals, power, and mobility markets.

09:07 EDT Charles & Colvard enters retail partnership with Xcel Brands' Longaberger - Charles & Colvard (CTHR) announced a new strategic retail partnership with Xcel Brands' (XELB) Longaberger. In the near term, the relationship will showcase an assortment of its product brand Moissanite by Charles & Colvard on the Longaberger website.

09:06 EDT Casa Systems extends market leadership with next gen distributed access - Casa Systems announced that its innovative DA2200 Distributed Access node, the only FPGA-based, DOCSIS 4.0-ready Remote PHY node in the industry, has been successfully deployed with Tier 1 cable operators in North and South America. Setting new industry benchmarks for performance and flexibility, Casa Systems' DA2200 Distributed Access node provides cable operators with a flexible foundation that enables a smooth, cost-effective transition to distributed, cloud-native environments. "Casa Systems continues to lead the way with distributed access architecture solutions that are open, scalable, and interoperable and that feature the highest availability," said Weidong Chen, Chief Technical Officer at Casa Systems. "Unlike traditional ASIC-based solutions that employ a one-size-fits-all approach, our unique software design uses programmable FPGAs that are tailored to meet specific operator requirements with the ability to implement new features quickly and easily as their networks evolve. In the race to 10G, the DA2200 delivers unparalleled flexibility and performance to cable operators, while offering a path for future growth."

09:05 EDT Fiesta Restaurant appoints Dirk Montgomery as CEO - Fiesta Restaurant announced that the board of directors has appointed Dirk Montgomery as its permanent president and CEO, effective April 13. Montgomery has served as interim CEO since December 8, 2022 and previously served as CFO since September 9, 2019.

09:05 EDT Hillstream BioPharma selects OncoBay to advance development of HSB-1216 - Hillstream BioPharma has selected immune-oncology clinical research organization, OncoBay Clinical, to provide comprehensive clinical and regulatory support for the clinical development program for its lead drug candidate HSB-1216. HSB-1216, Hillstream's most advanced candidate, utilizes ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death of drug-resistant cancers. As part of the agreement, OncoBay Clinical's engagement will provide comprehensive clinical expertise across data management, statistical programming, scientific writing, regulatory affairs and clinical operations services for clinical, and observational studies. Additionally, OncoBay will leverage the support of a multitude of top scientific advisors and highly experienced teams to support Hillstream.

08:51 EDT Office Properties cuts quarterly dividend to 25c per share from 55c - This distribution will be paid to OPI's common shareholders of record as of the close of business on April 24, 2023 and distributed on or about May 18, 2023. As announced earlier this week, OPI plans to merge with Diversified Healthcare Trust (DHC).

08:49 EDT SAB Biotherapeutics granted Fast Track designation from FDA for SAB-176 - SAB Biotherapeutics announced that the US Food and Drug Administration, FDA, has granted Fast Track designation for SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains. SAB also received FDA guidance and regulatory alignment on advancing SAB-176 into the next phase of development through initiation of a Phase 2b dose-range finding efficacy and safety trial in patient populations at high-risk for developing severe disease. SAB-176 is a novel, highly potent immunotherapy that is grounded in fundamentals of the natural immune response to neutralize Type A and Type B influenza viruses, which mutate rapidly. SAB-176 is also being studied in emerging and mutating pandemic strains by targeting multiple epitopes of the virus rather than a single epitope. "We are pleased to receive the FDA Fast Track designation for SAB-176. Influenza continues to be one of the biggest public health challenges the world faces on a continuing basis, with an excessively high number of hospitalizations and deaths each year," said Eddie Sullivan, PhD, co-founder, President & CEO of SAB Biotherapeutics. "We are excited about the potential role SAB-176 can play in tackling a highly mutagenic pathogen like influenza." In addition to the Fast Track designation, SAB Biotherapeutics has also received FDA guidance and regulatory alignment on advancing SAB-176 into the next phase of development, including a Phase 2b trial study design.

08:46 EDT Flux Power to open new Atlanta facility - Flux Power announced it is opening a new Atlanta facility on May 1 to supplement its customer support services in response to growth in nationwide sales of lithium-ion battery packs. The Atlanta facility will enable faster response times to Flux Power's global Fortune 500 and 100 customer base, while also materially reducing costs associated with personnel travel and shipping of battery packs to and from the Company's headquarters in Vista, California.

08:45 EDT Society Pass' NusaTrip acquires Vietnam's VLeisure - NusaTrip announces the acquisition of VLeisure, a Ho Chi Minh City, Vietnam-based online B2B hotel platform servicing small-to-medium size hotels in Vietnam and empowering online and offline travel agencies to manage and distribute travel products and services. The VLeisure acquisition extends NusaTrip's base of operations and geographical reach outside of Indonesia for the first time. Going forward, NusaTrip will continue to acquire online and offline travel agencies in SEA as it builds a regional travel platform servicing the booming SEA travel market. Leveraging on SoPa's capital and NusaTrip's technology, VLeisure will market its hotel management SaaS products to small-to-medium size hotels initially in Vietnam and then to the rest of SEA. In addition, NusaTrip now acquires an operational foothold to significantly expand its B2C and B2B businesses in Vietnam. Dennis Nguyen, Society Pass Founder, Chairman and Chief Executive Officer and NusaTrip Chairman, expounds, "We happily welcome VLeisure into our ever-expanding NusaTrip ecosystem. VLeisure seamlessly blends into our user and merchant growth strategy. We combine NusaTrip's robust flight B2B technology and B2C operational breadth with VLeisure extensive hotel management software solutions. With Phan's significant experience and knowledge of the Vietnamese travel sector, I appoint him as the Managing Director of Nusatrip Vietnam. As Head of our Hotel Business, his expertise in hotel technology allows him to create unique travel goods and services that meet the demands of Vietnamese travellers."

08:41 EDT Wejo, TKB file form S-4 registration statement for business combination - Wejo Group (WEJO) and TKB Critical Technologies 1 (USCT) announced that they had filed with the U.S. Securities and Exchange Commission a registration statement on Form S-4, which contains a preliminary proxy statement/prospectus, in connection with their previously announced business combination. Wejo also announced that it had filed the first amendment to its previously filed shelf registration statement on Form S-3. Wejo and TKB had previously announced on January 10, 2023, a business combination. Wejo and TKB filed the S-4 and Wejo filed the S-3 at this time to further their plans in regard to these transactions. The proposed business combination is subject to the S-4 being declared effective by the SEC, and other customary closing conditions.

08:39 EDT Navigator announces fifth, final vessel acquisition under 60/40 joint venture - Navigator Holdings announces its fifth and final vessel acquisition planned under its 60/40 joint venture agreement with Greater Bay Gas, previously announced on September 30, 2022. The Joint Venture announced the purchase of the first four vessels between December 20, 2022 and March 27, 2023. The final vessel, renamed the Navigator Vega, is a 22,000 cbm liquefied ethylene gas carrier built in 2019 and was delivered today. As previously stated, all five vessels will continue to be commercially managed under the Luna Pool collaboration arrangement, and technical management will be provided by the third-party technical manager, PG Shipmanagement Pte. Ltd. of Singapore. This fifth delivery concludes the first multi-vessel acquisition under the Joint Venture, which was announced in September 2022 and has been completed considerably ahead of the anticipated fifteen-month delivery schedule.

08:37 EDT ToughBuilt reports $3.8M in Q1 sales through Amazon - ToughBuilt Industries (TBLT) announced that the Company's gross sales for the quarter ended March 31, 2023, through Amazon.com (AMZN) were $3.8 million. This represents a 10% revenue increase from the same quarter in 2022. ToughBuilt Chief Executive Officer, Michael Panosian, commented, "Amazon has been a driving contributor for ToughBuilt's overall revenue growth. We believe that our global online sales and brand expansion through Amazon will continue to promote ToughBuilt's long-term success." He continued, "ToughBuilt is fervently expanding its product portfolio and we anticipate that through this multi-category development, we will deepen our reach into new regions and continue to establish our dominance as a premium-quality home improvement manufacturer, worldwide."

08:36 EDT Ocean Biomedical jumps 11% to $4.99 after USPTO notice of allowance in malaria

08:34 EDT Surgalign announces receipt of Nasdaq deficiency notice - Surgalign announced that on April 10, 2023, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company that it is no longer in compliance with the $10 million minimum stockholders' equity requirement for continued listing on the NASDAQ Global Select Market under Nasdaq Listing Rule 5450(b)(1)(A). The notification letter further indicated that the Company does not meet alternative standards set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq Global Select Market. This notification has no immediate effect on the Company's listing or in the trading of its Company's common stock on the Nasdaq. Under Nasdaq rules, the Company has 45 calendar days to submit a plan to regain compliance which may include, among other things, an application to transfer its common stock listing to the NASDAQ Capital Market. The Company intends to submit to Nasdaq on or before May 25, 2023 a plan to regain compliance.

08:33 EDT Galecto to present two posters at AACR annual meeting 2023 - Galecto announced it will present two posters at the upcoming American Association for Cancer Research, AACR, Annual Meeting 2023, taking place April 14-19 in Orlando, Florida. Galecto is currently conducting a Phase 2a trial of GB1211, a small molecule galectin-3 inhibitor, in combination with atezolizumab for the first-line treatment of non-small cell lung cancer. Many tumors overexpress galectin-3, which is linked to several cancer promoting mechanisms, including those linked to checkpoint inhibitor and chemotherapy resistance, and may ultimately lead to worse clinical outcomes. Several other forms of galectins, such as galectin-1, are also associated with cancer. The data to be presented at AACR suggests that both selective inhibition of galectin-1 and dual inhibition of galectin-1 and galectin-3 could provide potential cancer therapies, either alone or combination with immune checkpoint inhibitors, to boost immune infiltration and/or activation in the tumor microenvironment of lung adenocarcinoma, pancreatic cancer and other aggressive cancers.

08:32 EDT ZimVie announces recent launch of RegenerOss CC Allograft Particulate - ZimVie announced the recent launches of two additions to its biomaterials portfolio, the RegenerOss CC Allograft Particulate, a natural blend of cortical and cancellous bone particles that can be used to fill bony voids in a variety of dental applications, and the RegenerOss Bone Graft Plug, an easy-to-use grafting solution for filling extraction sockets and periodontal defects. Both grafts are now available across North America. "We are continuing to innovate and build on the core strengths of our dental portfolio through next-generation premium implants and abutments, additional modules within our digital dentistry suite, and now an expanded solution set in biomaterials," said Indraneel Kanaglekar, SVP and President of ZimVie Dental. "Our RegenerOss solutions provide greater options to customers and patients, and nicely complement our existing offering of clinically successful bone grafts."

08:14 EDT Corning, MSK announce health equity fellowship to explore disparities in cancer - Corning Incorporated and Memorial Sloan Kettering Cancer Center, MSK, announced that Dr. Francisco Sanchez-Vega, Ph.D., has been awarded the Corning-MSK Health Equity Research Fellowship, a two-year grant that funds research into the broad disparities in cancer outcomes for patients in historically underserved communities. Sponsored by Corning's Office of Racial Equality and Social Unity, the fellowship will allow Dr. Sanchez-Vega, an assistant attending computational oncologist in MSK's Colorectal Cancer Service in the Department of Surgery, to research the genomic, clinical, and socioeconomic causes behind the disproportionately negative outcomes of colorectal cancer in Black communities across the United States.

08:10 EDT Ocean Biomedical announces notice of allowance from USPTO for malaria therapy - Ocean Biomedical announced that its Scientific Co-founder and a member of its board of directors, Jonathan Kurtis, MD, PhD, received a Notice of Allowance from the United States Patent and Trademark Office, USPTO, for his U.S. patent application covering a therapeutic and prophylactic monoclonal antibody that kills falciparum malaria parasites. Building on his groundbreaking discovery that PfGARP is potentially a highly effective vaccine target for malaria, Dr. Kurtis has now discovered and produced a monoclonal antibody that binds to PfGARP and triggers the malaria parasite to kill itself. This new patent allowance will allow Dr. Kurtis' team to pursue development of this monoclonal antibody as both a potential therapeutic drug for individuals with severe malaria infection as well as a potential short-term prophylactic treatment to prevent malaria infection in travelers, overseas deployed military and government personnel, and individuals living in areas with short malaria transmission seasons.

08:09 EDT Walgreens and Prothena team to increase enrollment in Alzheimer's trial - Walgreens (WBA) and Prothena (PRTA) announced a collaboration to accelerate patient identification and recruitment for Prothena's ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety and tolerability of PRX012, a potential best-in-class anti-amyloid beta antibody under development for the treatment of Alzheimer's disease. As part of the collaboration, Walgreens will leverage its national footprint, portfolio of industry-leading healthcare companies and compliance framework to match patient populations to this Prothena clinical trial for PRX012, which has been granted Fast Track designation by the U.S. Food and Drug Administration

08:04 EDT Apple intends to use 100% recycled cobalt in batteries by 2025 - Apple announced a major acceleration of its work to expand recycled materials across its products, including a new 2025 target to use 100% recycled cobalt in all Apple-designed batteries. Additionally, by 2025, magnets in Apple devices will use entirely recycled rare earth elements, and all Apple-designed printed circuit boards will use 100% recycled tin soldering and 100% recycled gold plating. In 2022, the company significantly expanded its use of key recycled metals, and now sources over two-thirds of all aluminum, nearly three-quarters of all rare earths, and more than 95% of all tungsten in Apple products from 100% recycled material. This rapid progress brings Apple closer to its aim to one day make all products with only recycled and renewable materials, and advances the company's 2030 goal to make every product carbon neutral. The company said, "Apple has significantly expanded the use of 100 percent certified recycled cobalt over the past three years, making it possible to include in all Apple-designed batteries by 2025. In 2022, a quarter of all cobalt found in Apple products came from recycled material, up from 13 percent the previous year. Cobalt is a critical material in the batteries used in most consumer electronics, including Apple devices, enabling high energy density while also meeting Apple's robust standards for longevity and safety. Apple-designed batteries found in iPhone(R), iPad(R), Apple Watch(R), MacBook(R), and many other products represent a significant majority of the company's use of cobalt. The company's use of 100 percent certified recycled rare earth elements has greatly expanded in the last year as well, going from 45 percent in 2021 to 73 percent in 2022. Since first introducing recycled rare earths in the Taptic Engine(R) of iPhone 11, Apple has expanded its use of the material across its devices, including in all magnets found in the latest iPhone, iPad, Apple Watch, MacBook, and Mac(R) models. As magnets are by far Apple's largest use of rare earths, the new 2025 target means nearly all rare earths in Apple products will soon be 100 percent recycled. As part of the accelerated new timeline, all Apple-designed printed circuit boards will use 100 percent certified recycled gold plating by 2025. This includes rigid boards, such as the main logic board, and flexible boards, like those connecting to the cameras or buttons in iPhone. Since pioneering an exclusively recycled supply chain for gold in the plating of the main logic board for iPhone 13, Apple has extended the material's use in additional components and products, including the wire of all cameras in the iPhone 14 lineup, and printed circuit boards of iPad, Apple Watch, AirPods Pro(R), MacBook Pro(R), Mac mini(R), and HomePod(R). Apple is also working to encourage broader adoption of recycled gold for non-custom components across the electronics industry. By 2025, the company will use 100 percent certified recycled tin soldering on all Apple-designed printed rigid and flexible circuit boards. In recent years, Apple's use of recycled tin has expanded to the solder of many flexible printed circuit boards across Apple products, with 38 percent of all tin used last year coming from recycled sources. The application of recycled tin across even more components is underway, and the company is engaging more suppliers in this effort. Innovation has also driven progress toward another of Apple's 2025 commitments: to eliminate plastics from the company's packaging. The development of fiber alternatives for packaging components like screen films, wraps, and foam cushioning has kept Apple on track toward this ambitious goal. To address the remaining 4 percent plastic in the company's packaging footprint, Apple is innovating to replace labels, lamination, and other small uses. In the last year, Apple developed a custom printer to introduce digital printing directly onto the boxes of iPhone 14 and iPhone 14 Pro, eliminating the need for most labels. And a new overprint varnish found in iPad Air(R), iPad Pro(R), and Apple Watch Series 8 packaging replaces the polypropylene plastic lamination found on boxes and packaging components. The innovation helped avoid over 1,100 metric tons of plastic and over 2,400 metric tons of carbon dioxide."

07:57 EDT Fastenal falls 3% after Q1 results to $50.87 - Shares of Fastenal are down 3% or $1.69 at $50.87 in pre-market trading despite a Q1 earnings beat as company gross margins slipped 90 bps from last year to 45.7%.

07:56 EDT Fastenal says Q1 gross margin declined to 45.7% vs. 46.6% last year - The company states: Our gross profit, as a percentage of net sales, declined to 45.7% in the first quarter of 2023 from 46.6% in the first quarter of 2022. The change in our gross profit percentage primarily reflected four items. First, customer and product mix reduced our gross margin percentage. We experienced relatively strong growth from Onsite customers and non-fastener products, each of which tend to have a lower gross margin percentage than our business as a whole. This impact widened slightly on a sequential basis. Second, lower product margins in certain of our other product categories reduced our gross margin percentage. The combination of elevated costs and normalization of product availability for less frequently sold, often non-standard products where there is less visibility into the supply chain has produced some gross margin pressure. We took actions in the first quarter of 2023 to begin to address these pressures. Third, we had higher organizational/overhead costs, primarily due to higher inbound freight costs and working capital needs being relieved from inventory and generating higher period costs. Fourth, freight expenses were favorable, partially offsetting the negative impacts of mix, product gross margin pressure, and organizational/overhead costs. This favorable impact was from costs related to importing product from overseas suppliers being below prior year levels, the volume of containers being imported from overseas suppliers being lower, and record domestic freight revenue leveraging what are relatively stable costs to support our captive fleet."

07:36 EDT Amazon.com CEO says AWS remains early in its adoption curve - In his annual shareholder letter, Amazon.com CEO Andy Jassy states: "AWS has an $85B annualized revenue run rate, is still early in its adoption curve, but at a juncture where it's critical to stay focused on what matters most to customers over the long-haul. Despite growing 29% year-over-year in 2022 on a $62B revenue base, AWS faces short-term headwinds right now as companies are being more cautious in spending given the challenging, current macroeconomic conditions. While some companies might obsess over how they could extract as much money from customers as possible in these tight times, it's neither what customers want nor best for customers in the long term, so we're taking a different tack. One of the many advantages of AWS and cloud computing is that when your business grows, you can seamlessly scale up; and conversely, if your business contracts, you can choose to give us back that capacity and cease paying for it. This elasticity is unique to the cloud, and doesn't exist when you've already made expensive capital investments in your own on-premises datacenters, servers, and networking gear. In AWS, like all our businesses, we're not trying to optimize for any one quarter or year. We're trying to build customer relationships that outlast all of us."Reference Link

07:33 EDT Camping World to acquire All Seasons RV in Bend, Oregon - Camping World Holdings announced an agreement to acquire All Seasons RV in Bend, Oregon. This acquisition is anticipated to close in the second quarter of 2023 and will increase the Company's Oregon location count to six. Marcus Lemonis, CEO and Chairman of Camping World commented, "All Seasons RV has been proudly serving Central Oregon for over 40 years, and this acquisition will add to our presence in the important Oregon market, solidifying our position as the leader in the state." All Seasons RV is located at 63195 NE Jamison St., Bend, OR 97703. The new SuperCenter will offer a wide range of new and used RVs from top brands along with a full assortment of RV and outdoor products and accessories and the entire portfolio of Good Sam products and services.

07:15 EDT Tonix Pharmaceuticals expedites fibromyalgia, chronic migraine programs - Tonix Pharmaceuticals announced that it is eliminating the interim analyses in its registration-enabling, confirmatory Phase 3 RESILIENT study of TNX-102 SL for fibromyalgia and its Phase 2 PREVENTION study of TNX-1900 for chronic migraine. The modifications to the RESILIENT and PREVENTION studies are designed to streamline the trials and to provide topline data for both programs in 2023. Target enrollment for the core TNX-102 SL fibromyalgia study remains approximately 470 participants while target enrollment for the TNX-1900 chronic migraine study will be reduced from approximately 300 participants to approximately 150 participants, to accommodate the new topline timing. Key Anticipated 2023 Milestones: Updated Guidance: Eliminating interim analysis of Phase 3 RESILIENT study of TNX-102 SL for fibromyalgia. Eliminating interim analysis of Phase 2 PREVENTION study of TNX-1900 for chronic migraine; topline results now expected in the fourth quarter of 2023. Unchanged Guidance: Topline results of Phase 3 RESILIENT study of TNX-102 SL for fibromyalgia in the fourth quarter of 2023. Topline results of Phase 2 PREVAIL study of TNX-102 SL for fibromyalgia-type Long COVID in the third quarter of 2023. Interim analysis results of Phase 2 UPLIFT study of TNX-601 ER for major depressive disorder in the fourth quarter of 2023. Initiate enrollment in a potentially pivotal Phase 2 study of TNX-1300 for the treatment of cocaine intoxication in the second quarter of 2023. Initiate enrollment in a Phase 1 study of TNX-1500 for the prophylaxis of rejection in kidney transplantation in the second quarter of 2023. Initiate enrollment in a Phase 1 study of TNX-801, a potential vaccine to protect against smallpox and mpox, in the second half of 2023. Continue development of TNX-2900, a small peptide for the treatment of hyperphagia in Prader-Willi syndrome, for which the FDA has granted Orphan Drug designation.

07:12 EDT Plymouth Industrial REIT development projects earn Green Globes certification - Plymouth Industrial REIT announced that all four projects in the first phase of the Company's development program have achieved Green Globes certification for Core & Shell Construction for sustainability efforts during the design and delivery process. Jeff Witherell, Chief Executive Officer and Co-Founder of Plymouth, noted, "We take our responsibilities for the environment very seriously with a goal of reducing energy consumption and increasing our use of renewable energy. Joining GBI in 2022 was consistent with this goal as well as a long history of operating with integrity - one of our three founding pillars. We are pleased to receive a Two Green Globes ranking on three of the developments and a Three Green Globes certification on a fourth. Plymouth has also made significant progress on environmental projects that have positive bottom-line impacts for us and for our tenants such as LED lighting conversions, cool roofs and solar power."

07:10 EDT Lifeist Wellness' Mikra announces study results for CELLF - Lifeist Wellness announced that its U.S. biosciences subsidiary Mikra Cellular Sciences has completed its first foundational pre-clinical study aimed at understanding the effect of CELLF on healthspan and lifespan. Mikra partnered with InVivo Biosystems to test whether CELLF could improve healthspan and protect against reactive oxygen species. The researchers identified non-toxic concentrations of CELLF and found that it increased both lifespan and healthspan in animals, especially late in life. Additionally, researchers found that treatment with CELLF resulted in differential gene expression profiles, particularly affecting key members of established longevity pathways such as insulin/insulin-like growth factor-1 signaling, autophagy/mTOR pathway, and stress response pathway. Lastly, it was observed that CELLF had antioxidant properties and reduced the damage caused by exposure to pesticides in the study.

07:07 EDT Biosynex extends tender offer for shares of Chembio Diagnostics - Biosynex announced that Project Merci Merger Sub, a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock of Chembio Diagnostics at a price of $0.45 per Share, net to the seller in cash, without interest and subject to any required tax withholding, until 6:00 p.m., New York City time on April 26, 2023, unless further extended. The tender offer was previously scheduled to expire at 6:00 p.m., New York City time, on April 12, 2023. All other terms and conditions of the tender offer remain unchanged.

07:06 EDT Barrick Gold reports preliminary Q1 sales, production of gold, copper - Barrick Gold Corporation reported preliminary Q1 sales of 0.95 million ounces of gold and 89 million pounds of copper, as well as preliminary Q1 production of 0.95 million ounces of gold and 88 million pounds of copper. As previously guided, Barrick's gold production in 2023 is expected to increase through the year with the first quarter being the lowest, while copper production is expected to be higher in the second half of the year. The company remains on track to achieve its full year gold and copper guidance. As previously guided, preliminary Q1 gold production was lower than Q4 2022 primarily as a result of lower production at Carlin, mainly due to annual roaster maintenance resulting in lower throughput at Goldstrike, the conversion of the Goldstrike autoclave to a conventional carbon-in-leach process and a harsh winter in northern Nevada impacting operations. Preliminary Q1 copper production was lower than Q4 2022, driven by lower production at Lumwana and Zaldivar, as expected.

07:05 EDT Stratasys board rejects Nano Dimension revised proposal of $20.05 per share - Stratasys (SSYS) announced that its Board of Directors has unanimously rejected the revised unsolicited proposal received from Nano Dimension ( NNDM) on April 3 to acquire Stratasys for $20.05 per share in cash. Consistent with its fiduciary duties, and in consultation with its independent financial and legal advisors, the Stratasys Board of Directors carefully reviewed and evaluated the revised proposal. Following its review, the Stratasys Board concluded that Nano's proposal continues to substantially undervalue Stratasys in light of its standalone prospects and is not in the best interests of Stratasys and its shareholders. Additionally, the general composition and legitimacy of Nano's board and management, and authority to submit and follow through on a bona fide acquisition proposal, remain unclear due to Nano's pending court litigation with its largest shareholder, Murchinson Ltd. Murchinson requisitioned a meeting of Nano shareholders to, among other things, remove Nano CEO Mr. Yoav Stern and three other Nano directors and elect two new directors, with the goal of "reporting out to shareholders within 60 days of new directors being seated a cohesive strategy for enhancing value." Murchinson announced that the Nano shareholder meeting was held on March 20, and that all of the changes regarding the composition of Nano's board, including the removal of Mr. Stern, were approved by 92% of the Nano shares voting. Murchinson, Nano and Mr. Stern are now involved in litigation as to who in fact is currently leading Nano. Thus, Nano's revised proposal, in addition to substantially undervaluing Stratasys, is subject to significant uncertainty as to the composition, leadership and decision-making authority of Nano's board. In this regard, the Stratasys Board and management team are concerned that a take-over proposal while Nano's authority is unclear legally and subject to a court ruling would expose Stratasys, its shareholders and other stakeholders to the harmful spillover effects of what, in Stratasys' judgment, is an unprecedented and confusing situation. The Stratasys Board and management team are committed to enhancing shareholder value and continue to successfully execute on the company growth strategy, taking steps to achieve that objective. J.P. Morgan is acting as financial advisor to Stratasys, and Meitar Law Offices and Wachtell, Lipton, Rosen & Katz are serving as legal counsel.

07:04 EDT Mind Medicine appoints Mark Sullivan as chief legal officer - Mind Medicine announced the appointment of Mark Sullivan, effective immediately, as chief legal officer and corporate secretary. Sullivan is an experienced public company general counsel and corporate secretary, with extensive expertise and demonstrated success in the areas of SEC reporting, financing, corporate governance and compliance, mergers and acquisitions, intellectual property, litigation management and business development. Prior to joining the company, Sullivan was the general counsel and corporate secretary of Sesen Bio, a biopharmaceutical company from August 2019 to April.

07:03 EDT Stratasys board rejects Nano Dimension revised proposal of $20.05 per share

07:01 EDT Atai Life Sciences doses first subject in Phase 1 study of PCN-101 in depression - Atai Life Sciences announced that the first subject has been dosed in Perception Neuroscience's Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 - R-ketamine -. This Phase 1 open-label study is designed to assess the safety, tolerability, and pharmacokinetic profile of 60mg, 90mg and 120mg of PCN-101 delivered subcutaneously as compared to 60mg of PCN-101 delivered intravenously. The trial will enroll approximately 16 healthy volunteers across the four cohorts and is expected to be completed in the middle of 2023. This IV-to-subcutaneous bridging study will potentially inform dosing regimens of the new subcutaneous formulation that may optimize the therapeutic index-the balance of safety, tolerability and efficacy-of PCN-101 in future studies, thereby supporting further exploration of the potential of R-ketamine as a rapid acting anti-depressant for at-home use.Perception Neuroscience is a New York City- based biopharmaceutical company committed to developing therapies for neuropsychiatric diseases. The company is a majority-owned subsidiary of atai Life Sciences.

06:46 EDT Lazard reports preliminary AUM $232.1B as of March 31 - The month's AUM included market appreciation of $2.8B, net inflows of $2.8B, which includes approximately $3.9B from the acquisition of Truvvo Partners, and foreign exchange appreciation of $2.3B. Preliminary average AUM for the quarter ended March 31 was $226.8B.

06:18 EDT KBR signs MoU with Atlas Agro to license K-GreeN technology - KBR announced that it has signed a memorandum of understanding, or MoU, with Atlas Agro to license KBR's K-GreeN technology for Atlas' planned investment in a series of green nitrate plants. Under the terms of the MoU, KBR will provide technology licensing, basic engineering design, proprietary equipment and catalyst for the plants, which will produce zero-carbon nitrogen fertilizers. The engineering design for the first plant located in the United States commenced in March 2023.

06:10 EDT Garrett Motion signs capital structure agreements with Centerbridge and Oaktree - Garrett Motion has entered into definitive agreements with Centerbridge Partners and funds managed by Oaktree Capital Management to simplify the company's capital structure by converting all outstanding Series A Preferred Stock into a single class of Common Stock, on or about July 3, 2023, subject to certain conditions. The agreements contemplate the repurchase of approximately $285M of Series A Preferred Stock from each of Centerbridge and Oaktree at a market-based price, without premium, and provide for a reduction in governance rights, as well as lock-up and other agreements. The elimination of the Series A Preferred dividend adds over $100M of incremental annual net cash flow to support investments. The company's Series A Cumulative Convertible Preferred Stock will convert into shares of the company's Common Stock on or about July 3. The company has agreed to repurchase approximately $280M of Series A Preferred Stock from Centerbridge and approximately $290M of Series A Preferred Stock from Oaktree for a total of $570M, reducing Centerbridge's ownership from 22% to 15% and Oaktree's ownership from 23% to 15%. Centerbridge and Oaktree will be paid a cash purchase price of $8.10 per repurchased share. All holders of Series A Preferred Stock will receive an amount equal to: 17c per share, the preference dividends that will accrue on the Series A preferred Stock through June 30; approximately $0.6835 per share, the accrued and unpaid preference dividends on the Series A Preferred Stock as of June 30; and $0.144375 per share, the preference dividends that would have accrued through September 30. The repurchases are subject to obtaining funding of approximately $700M of new debt, which is expected to be in the form of a new term loan B under the company's existing credit agreement, expected to be consummated in Q2. Garrett has also announced an increase in the company's share repurchase authorization to $250M. Centerbridge and Oaktree will reduce their governance rights and lock up their remaining shares, while remaining the company's largest shareholders and maintaining one board seat each.

05:05 EDT ZF to purchase silicon carbide devices from STMicroelectronics from 2025 - ZF will, from 2025, purchase silicon carbide devices from STMicroelectronics. Under the terms of the multi-year contract, ST will supply a volume of double-digit millions of silicon carbide devices to be integrated in ZF's new modular inverter architecture going into series production in 2025. ZF will leverage ST's vertically integrated silicon carbide manufacturing in Europe and Asia to secure customer orders in electromobility. ST will manufacture the silicon carbide chips at its production fabs in Italy and Singapore with packaging of the chips into STPAK, an ST-developed advanced package, and testing at its back-end facilities in Morocco and China. ST will supply ZF from 2025 with a volume of double-digit millions of third generation silicon carbide Mosfet devices. ZF can connect a variable number of such devices together to match customers' performance requirements without changing the design of the inverter. Among others, ZF will use the technology in inverters for vehicles of a European car manufacturer whose production start is planned for 2025.